Análisis de la acción AxoGen, Inc. (AXGN)AXGNAxoGen, Inc.

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix, and NerveTape. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

AxoGen Inc. (AXGN) is a good buy right now due to its current price of $38.06 being significantly below analyst targets, with BofA setting a target of $52 and Barclays at $55. The recent acquisition of BioCircuit Technologies for $200 million is expected to enhance revenue growth and profitability, which is supported by a gross margin of 72.67% in Q2 2026. However, the risk is highlighted by a high forward P/E ratio of 102.04, indicating potential overvaluation if growth does not materialize as expected.

6 analysts cover AXGN: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 39.80.